Predicting response to cancer chemotherapy: The role of p53

Cell and Tissue Research

Volumn 292, Issue 3, 1998, Pages 435-445

  Weller, Michael ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Apoptosis; Cell cycle; Chemotherapy; Differentiation; p53

Indexed keywords

FAS ANTIGEN; FAS LIGAND; PROTEIN P21; PROTEIN P53;

APOPTOSIS; CANCER CHEMOTHERAPY; CELL DEATH; DRUG SENSITIVITY; GENE ACTIVATION; GENE DISRUPTION; IMMUNOCHEMISTRY; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVIEW; SINGLE STRAND CONFORMATION POLYMORPHISM; TRANSCRIPTION INITIATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; HUMANS; MICE; MICE, TRANSGENIC; NEOPLASMS, EXPERIMENTAL; PREDICTIVE VALUE OF TESTS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031869758     PISSN: 0302766X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004410051072     Document Type: Review

References (75)

1. Aas T, Borresen AL, Geisler S, Smith-Sorensen B, Johnsen H, Varhaug JE, Akslen LA, Lonning PE (1996) Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 2:811-814
2. An B, Dou QP (1996) Cleavage of retinoblastoma protein during apoptosis: an interleukin 1β-converting enzyme-like protease as candidate. Cancer Res 56:438-442
3. Bergh J, Norberg T, Sjögren S, Lindgren A, Holmberg L (1995) Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med 1: 1029-1034
4. Biard DSF, Martin M, Rhun Y, Duthu A, Lefaix JL, May E, May P (1994) Concomitant p53 gene mutation and increased radiosensitivity in rat lung embryo epithelial cells during neoplastic development. Cancer Res 54:3361-3364
5. Biernat W, Kleihues P, Yonekawa Y, Ohgaki H (1997) Amplification and overexpression of MDM2 in primary (de novo) glioblastomas. J Neuropathol Exp Neurol 56:180-185
6. Blagosklonny MV, El-Deiry WS (1996) In vitro evaluation of a p53-expressing adenovirus as an anticancer drug. Int J Cancer 67:386-392
7. Bosari S, Viale G, Radaeli U, Bossi P, Bonoldi E, Coggi G (1993) p53 accumulation in ovarian carcinomas and its prognostic implications. Hum Pathol 24:1175-1179
8. Brachman DG, Beckett M, Graves D, Haraf D, Yokes E, Weichselbaum RR (1993) p53 mutation does not correlate with radiosensitivity in 24 head and neck cancer cell lines. Cancer Res 53:3667-3669
9. Bristow RG, Benchimol S, Hill RP (1996) The p53 gene as a modifier of intrinsic radiosensitivity: implications for radiotherapy. Radiother Oncol 40:197-223
10. Buttitta F, Marchetti A, Gadduci A, Pellegrini S, Morganti M, Carnicelli V, Cosio S, Gagetti O, Genazzanui AR, Bevilaqua G (1997) p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study. Br J Cancer 75:230-235
11. Caelles C, Helmberg A, Karin M (1994) p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature 370:220-223
12. Chresta CM, Masters JRW, Hickman JA (1996) Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p53 and a high bax:bcl-2 ratio. Cancer Res 56:1834-1841
13. Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML, Wyllie AH (1993) Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362:849-852
14. Clarke AR, Howard LA, Harrison DJ, Winton DJ (1997) p53, mutation frequency and apoptosis in the murine small intestine. Oncogene 14:2015-2018
15. Dittmer S, Pati S, Zambetti G, Chu S, Teresky AK, Moore M, Foster D, Anderson RJ, Levine AJ (1993) Gain of function mutations in p 53. Nat Genet 4:42-46
16. Eliopoulos AG, Kerr DJ, Herod J, Hodgkins L, Krajewski S, Reed JC, Young LS (1995) The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and bcl-2. Oncogene 11:1217-1228
17. Fan S, El-Deiry WS, Bae I, Freeman J, Jondle D, Bhatia K, Fornace AJ, Magrath I, Kohn KW, O'Connor PM (1994) p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res 54:5824-5830
18. Fan S, Smith ML, Rivet DJ, Duba D, Zhan Q, Kohn KW, Fornace AJ, O'Connor PM (1995) Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res 55:1649-1654
19. Friesen C, Herr I, Krammer PH, Debatin KM (1996) Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med 2:574-577
20. Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB, Roth JA (1994) Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res 54:2287-2291
21. Gallagher WM, Cairney M, Schott B, Rominson IB, Brown R (1997) Identification of p53 genetic suppressor elements which confer resistance to cisplatin. Oncogene 14:185-193
22. Gallardo D, Drazan KE, McBride WH (1996) Adenovirus-based transfer of wild-type p53 gene increases ovarian tumor radiosensitivity. Cancer Res 56:4891-4893
23. Gjerset R, Turia ST, Sobol RE, Scalise JJ, Mercola D, Collins H, Hopkins PJ (1995) Use of wild-type p53 to achieve complete treatment sensitization of tumor cells expressing endogenous mutant p53. Mol Carcinog 14:275-285
24. Greenblatt MS, Bennett WP, Hollstein M, Harris CC (1994) Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54:4855-4878
25. Hamada M, Fujiwara T, Hizuta A, Gochi A, Naomoto Y, Takakura N, Takahashi K, Roth JA, Tanaka N, Orita K (1996) The p53 gene is a potent determinant of chemosensitivity and radiosensitivity in gastric and colorectal cancers. J Cancer Res Clin Oncol 122:360-365
26. Han JW, Dionne CA, Kedersha NL, Goldmacher VS (1997) p53 status affects the rate of the onset but not the overall extent of doxorubicin-induced cell death in Rat-1 fibroblasts constitutively expressing c-myc. Cancer Res 57:176-182
27. Haupt Y, Rowan S, Shaulian E, Vousden HK, Oren M (1995) Induction of apoptosis in HeLa cells by transactivation deficient p53. Genes Dev 9:2170-2183
28. Hawkins DS, Demers GW, Galloway DA (1996) Inactivation of p53 enhances sensitivity to multiple chemotherapeutic drugs. Cancer Res 56:892-898
29. Hawley RS, Friend SH (1996) Strange bedfellows in even stranger places: the role of ATM in meiotic cells, lymphocytes, tumors, and its functional links to p53. Genes Dev 10:2383-2388
30. Iwadate Y, Fujimoto S, Tagawa M, Namba H, Sueyoshi K, Hirose M, Sakiyama S (1996) Association of p53 gene mutation with decreased chemosensitivity in human malignant gliomas. Int J Cancer 69:236-240
31. Kimuru M, Tagawa M, Takenaga K, Yamaguchi T, Saisho H, Nakagawara A, Sakiyama S (1997) Inability to induce the alteration of tumorigenicity and chemosensitivity of p53-null human pancreatic carcinoma cells after the transduction of wild-type p53 gene. Anticancer Res 17:879-884
32. Koechli OR, Schaer GN, Seifert B, Hornung R, Haller U, Eppenberger U, Mueller H (1994) Mutant p53 protein associated with chemosensitivity in breast cancer specimens. Lancet 344:1647-1648
33. Labrecque S, Matlashewski GJ (1995) Viability of wild type p53-containing and p53-deficient tumor cells following anticancer treatment: the use of human papillomavirus E6 to target p53. Oncogene 11:387-392
34. Lee JM, Bernstein A (1993) p53 mutations increase resistance to ionizing radiation. Proc Natl Acad Sci USA 90:5742-5746
35. Lee JM, Bernstein A (1995) Apoptosis, cancer and the p53 tumour suppressor gene. Cancer Metastasis Rev 14:149-161
36. Levine AJ (1997) p53, the cellular gatekeeper for growth and division. Cell 85:323-331
37. Lowe SW, Ruley HE, Jacks T, Housman DE (1993a) p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74:957-967
38. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T (1993b) p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362:847-849
39. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T (1994) p53 status and the efficacy of cancer therapy in vivo. Science 266:807-810
40. Makris A, Powels TJ, Dowsett M, Allred C (1995) p53 protein overexpression and chemosensitivity in breast cancer. Lancet 345:1181-1182
41. Malcomson RDG, Oren M, Wyllie AH, Harrison DJ (1995) p53-independent death and p53-induced protection against apoptosis in fibroblasts treated with chemotherapeutic drugs. Br J Cancer 72:952-957
42. Mathieu MC, Koscielny S, Bihan ML, Spielmann M, Arriagada M (1995) p53 protein overexpression and chemosensitivity in breast Cancer. Lancet 345:1182
43. McIlwrath AJ, Vasey PA, Ross GM, Brown R (1994) Cell cycle arrests and radiosensitivity of human tumor cell lines: dependence on wild-type p53 for radiosensitivity. Cancer Res 54:3718-3722
44. Merritt AJ, Potten CS, Kemp CJ, Hickman JA, Balmain A, Lane DP, Hall PA (1994) The role of p53 in spontaneous apoptosis and radiation-induced apoptosis in the gastrointestinal tract of normal and p53-deficient mice. Cancer Res 54:614-617
45. Michalowitz D, Halevy O, Oren M (1990) Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell 62:671-680
46. Morgan SE, Kastan MB (1997) p53 and ATM: cell cycle, cell death, and cancer. Adv Cancer Res 1-25
47. Müller H, Eppenberger U (1996) The dual role of mutant p53 protein in chemosensitivity of human cancers. Anticancer Res 16:3845-3848
48. Müller M, Strand S, Hug H, Heinemann EM, Walczak H, Hofmann WJ, Stremmel W, Krammer PH, Galle PR (1997) Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/ Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest 99:403-413
49. Nguyen DM, Spitz FR, Yen N, Cristiano RJ, Roth JA (1996) Gene therapy for lung cancer: enhancement of tumor suppression by a combination of sequential systemic cisplatin and adenovirus-mediated p53 gene transfer. J Thorac Cardiovasc Surg 112:1372-1377
50. Owen-Schaub LB, Zhang W, Cusack JC, Angelo LS, Santee SM, Fujiwara T, Roth JA, Deisseroth AB, Zhang WW, Kruzel E, Radinsky R (1995) Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol Cell Biol 15: 3032-3040
51. Paradiso A, Rabinovich M, Vallejo C, Machiavelli M, Romero A, Perez J, Lacava J, Cuevas MA, Rodriquez R, Leone B, Sapia MG, Simone G, De Lena M (1996) p53 and PCNA expression in advanced colorectal cancer: response to chemotherapy and long-term prognosis. Int J Cancer 69:437-441
52. Perego P, Giarolo M, Righetti SC, Supino R, Caserini C, Delia D, Pierotti MA, Miyashita T, Reed JC, Zunino F (1996) Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res 56:556-562
53. Petty RD, Cree IA, Sutherland LA, Hunter EM, Lande DP, Preece PE, Andreotti PE (1994) Expression of the p53 tumour suppressor gene product is a determinant of chemosensitivity. Biochem Biophys Res Commun 199:264-270
54. Pirollo KF, Hao Z, Rait A, Jang YJ, Fee WE, Ryan P, Chiang Y, Chang EH (1997) p53 mediated sensitization of squamous all carcinoma of the head and neck to radiotherapy. Oncogene 14:1735-1746
55. Pohl U, Trepel M, Naumann U, Dichgans J, Weller M (1997) p53 gene transfer in human malignant glioma: effects on susceptibility to apoptosis (abstract). 6. Arbeitstagung der Deutschen Arbeitsgemeinschaft für Gentherapie. Ulm, 1997
56. Righetti SC, Della Torre G, Pilotti S, Ménard S, Ottone F, Colnaghi MI, Pierotti MA, Lavarino C, Cornarotti M, Oriana S, Böhm S, Bresciani GL, Spatti G, Zunino F (1996) A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res 56:689-693
57. Roth W, Fontana A, Trepel M, Dichgans J, Reed JC, Weller M (1997a) Immunochemotherapy of malignant glioma: synergistic activity of CD95 ligand and chemotherapeutics. Cancer Immunol Immunother 44:55-63
58. Roth W, Wagenknecht B, Grimmel C, Dichgans J, Weller M (1997b) Taxol-mediated augmentation of CD95 ligand-induced apoptosis of human malignant glioma cells is independent of p53 induction and G2/M cell cycle arrest. Br J Cancer (in press)
59. Rusch V, Klimstra D, Venkatraman E, Oliver J, Martini N, Gralla R, Kris M, Dmitrovsky E (1995) Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. Cancer Res 55:5038-5042
60. Siles E, Villalobos M, Valenzuela MT, Núñez MI, Gordon A, McMillan TJ, Pedraza V, Ruiz de Almodóvar JM (1996) Relationship between p53 status and radiosensitivity in human tumour cell lines. Br J Cancer 73:581-588
61. Skladanowski A, Larsen AK (1997) Expression of wild-type p53 increases etoposide cytotoxicity in M1 myeloid leukemia cells by facilitated GT to M transition: implications for gene therapy. Cancer Res 57:818-823
62. Slichenmyer WJ, Nelson WG, Slebos RJ, Kastan MB (1993) Loss of a p53-associated G1 checkpoint does not decrease cell survival following DNA damage. Cancer Res 53:4164-4168
63. Trepel M, Scheding S, Groscurth P, Horny HP, Malipiero U, Brugger W, Dichgans J, Weller M (1997) A new look at the role of p53 in leukemia cell sensitivity to chemotherapy. Leukemia 11:1842-1849
64. Trepel M, Groscurth P, Malipiero U, Gulbins E, Dichgans J, Weller M (1998) Chemosensitivity of human malignant glioma: modulation by p53 gene transfer. J Neurooncol (in press)
65. Tsang NM, Nagasawa H, Li C, Little JB (1995) Abrogation of p53 function by transfection of HPV 16 E6 gene enhances the resistance of human diploid fibroblasts to ionizing radiation. Oncogene 10:2403-2408
66. Vasey PA, Jones NA, Jenkins S, Dive C, Brown R (1996) Cisplatin, camptothecin, and taxol sensitivities of cells with p53-associated multidrug resistance. Mol Pharmacol 50:1536-1540
67. Vikhanskaya F, D'Incalci M, Broggini M (1995) Decreased cytotoxic effects of doxorubicin in a human ovarian cancer-cell line expressing wild-type p53 and WAF/CIP1 genes. Int J Cancer 61:397-401
68. Wada M, Bartram CR, Nakamura H, Hachiya M, Chen DL, Borenstein J, Miller CW, Ludwig L, Hansen-Hagge TE, Ludwig WD, Reiter A, Mizoguchi H, Koeffler HP (1993) Analysis of p53 mutations in a large series of lymphoid hematologic malignancies of childhood. Blood 82:3163-3169
69. Wagenknecht B, Trepel M, Von Deimling A, Grimmel C, Rollbrocker B, Hayashi Y, Lang F, Dichgans J, Gulbins J, Weller M (1997) p53 accumulation promotes dephosphorylation and proteolytic cleavage of retinoblastoma protein in human malignant glioma cells. Cell Physiol Biochem 7:304-311
70. Wahl AF, Donaldson KL, Fairchild C, Lee FYF, Foster SA, Demers GW, Galloway DA (1996) Loss of normal p53 function confers sensitization to taxol by increasing G2/M arrest and apoptosis. Nat Med 2:72-79
71. Wang XW, Harris CC (1996) TP53 tumour suppressor gene: clues to molecular carcinogenesis and cancer therapy. Cancer Surv 28:169-196
72. Wang XW, Vermeulen W, Coursen JD, Gibson M, Lupold SE, Forrester K, Xu G, Elmore L, Yeh H, Hoeijmakers JHJ, Harris CC (1996) The XPB and XPD DNA helicases are components of the p53-mediated apoptosis pathways. Genes Dev 10:1219-1232
73. Wilson WH, Teruya-Feldstein J, Fest T, Harris C, Steinberg SM, Jaffe ES, Raffeid M (1997) Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas. Blood 89:601-609
74. Winter S, Roth W, Dichgans J, Weller M (1997) Synergistic activity of CD95 ligand and teniposide (VM26) does not involve enhanced formation of cleavable DNA complexes or changes in CD95/CD95 ligand expression. Eur J Pharmacol (in press)
75. Wu GS, El-Deiry WS (1996) p53 and chemosensitivity. Nat Med 2:255-256